In an effort to create a molecule that absorbs further into the optimum window for photochemotherapy (PCT), the new cyclometallated complex [Ru(biq)2(phpy)](PF6) (1, biq = 2,2'-biquinoline, phpy(-) = deprotonated 2-phenylpyridine) was synthesized, characterized and compared to the known photoactive complexes [Ru(biq)2(bpy)](PF6)2 (2, bpy = 2,2'-bipyridine) and [Ru(biq)2(phen)](PF6)2 (3, phen = 1,10-phenanthroline), both of which undergo exchange of one biq ligand when irradiated with red light in coordinating solvents. Excited state ligand dissociation in 2 and 3 is believed to be related to the steric hindrance afforded by the presence of two coordinated biq ligands. The ligand exchange quantum yield of 2 is ~2-fold greater than that of 3, which was shown to be cytotoxic when irradiated with visible light. Cyclometallation results in a red shift of the MLCT absorption maximum of ` by ~100 nm relative to those of 2 and 3, but, although 1 exhibits a distorted octahedral geometry, photoinduced ligand exchange does not occur. DFT calculations were used to aid in our understanding of the lack of photochemistry of 1 which is explained by the destabilization of the eg(σ*) orbitals upon cyclometallation.